1. Eli Lilly. REYVOW (lasmiditan) tablets, for oral use [controlled substance schedule pending]: US prescribing information. 2019. http://pi.lilly.com/. Accessed 11 Nov 2019.
2. US Food & Drug Administration (FDA). FDA approves new treatment for patients with migraine [media release]. 11 Oct 2019. http://www.fda.gov.
3. Moreno-Ajona D, Chan C, Villar-Martínez MD, et al. Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review. Headache. 2019;59(Suppl 2):3–19.
4. Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15(2):291–303.
5. Eli Lilly. Lilly’s REYVOW™ (lasmiditan), the first and only medicine in a new class of acute treatment for migraine, receives FDA approval [media release]. 11 Oct 2019. http://www.prnewswire.com.